Literature DB >> 1969271

How does convulsive therapy work?

M Fink1.   

Abstract

There is no death of hypotheses to explain the antidepressant action of convulsive therapy. Neurohumoral-receptor, kindling-anticonvulsant, and neuroendocrine ideas are prominently discussed. Views based on direct comparisons with antidepressant drugs or based on pharmacologic models are seen as inadequate. The neuroendocrine hypothesis, derived from human studies, appears the most viable. It argues that the affective disorders result from a deficiency of a mood-modifying peptide (antidepressin) derived from the hypothalamus. Convulsive therapy stimulates the production and release of antidepressin. Studies dedicated to the search for this peptide as a replacement for ECT are encouraged.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969271

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  5 in total

1.  Electroconvulsive shock induces neuron death in the mouse hippocampus: correlation of neurodegeneration with convulsive activity.

Authors:  I I Zarubenko; A A Yakovlev; M Yu Stepanichev; N V Gulyaeva
Journal:  Neurosci Behav Physiol       Date:  2005-09

Review 2.  Guide to anaesthetic selection for electroconvulsive therapy.

Authors:  Klaus J Wagner; Oliver Möllenberg; Michael Rentrop; Christian Werner; Eberhard F Kochs
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

4.  Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures.

Authors:  N Hiroi; G J Marek; J R Brown; H Ye; F Saudou; V A Vaidya; R S Duman; M E Greenberg; E J Nestler
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

5.  Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.

Authors:  Kouhei Kitagawa; Yoshihisa Kitamura; Toshiaki Miyazaki; Junya Miyaoka; Hiromu Kawasaki; Masato Asanuma; Toshiaki Sendo; Yutaka Gomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-03-10       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.